Literature DB >> 20220774

CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.

T Vaisitti1, S Aydin, D Rossi, F Cottino, L Bergui, G D'Arena, L Bonello, A L Horenstein, P Brennan, C Pepper, G Gaidano, F Malavasi, S Deaglio.   

Abstract

Homing of chronic lymphocytic leukemia (CLL) cells to sites favoring growth, a critical step in disease progression, is principally coordinated by the CXCL12/CXCR4 axis. A cohort of 62 CLL patients was divided into migrating and nonmigrating subsets according to chemotaxis toward CXCL12. Migrating patients phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) proteins more than nonmigrating patients (P<0.0002). CD38 expression was the parameter most strongly associated with heightened CXCL12 signaling (P<0.0001), confirmed by independent statistical approaches. Consistent with this observation, CD38(-) CLL cells in samples with bimodal CD38 expression responded less to CXCL12 than the intact clone (P=0.003). Furthermore, lentivirus-induced de novo expression of CD38 was paralleled by increased responses to CXCL12, as compared with cells infected with a control virus. CD38 ligation with agonistic monoclonal antibodies (mAbs) enhanced CXCL12 signaling, whereas blocking anti-CD38 mAbs inhibited chemokine effects in vitro. This is attributed to physical proximity on the membrane between CD38 and CXCR4 (the CXCL12 receptor), as shown by (i) coimmunoprecipitation and (ii) confocal microscopy experiments. Blocking anti-CD38 mAbs significantly compromised homing of CLL cells from blood to lymphoid organs in a mouse model. These results indicate that CD38 synergizes with the CXCR4 pathway and support the working hypothesis that migration is a central step in disease progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20220774     DOI: 10.1038/leu.2010.36

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  41 in total

Review 1.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

2.  The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

Authors:  Alba Matas-Céspedes; Anna Vidal-Crespo; Vanina Rodriguez; Neus Villamor; Julio Delgado; Eva Giné; Heleia Roca-Ho; Pablo Menéndez; Elías Campo; Armando López-Guillermo; Dolors Colomer; Gaël Roué; Adrian Wiestner; Paul W H I Parren; Parul Doshi; Jeroen Lammerts van Bueren; Patricia Pérez-Galán
Journal:  Clin Cancer Res       Date:  2016-09-16       Impact factor: 12.531

3.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Authors:  Davide Bagnara; Matthew S Kaufman; Carlo Calissano; Sonia Marsilio; Piers E M Patten; Rita Simone; Philip Chum; Xiao-Jie Yan; Steven L Allen; Jonathan E Kolitz; Sivasubramanian Baskar; Christoph Rader; Hakan Mellstedt; Hodjattallah Rabbani; Annette Lee; Peter K Gregersen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

4.  Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells.

Authors:  Silvia Mele; Stephen Devereux; Andrea G Pepper; Elvira Infante; Anne J Ridley
Journal:  Blood Adv       Date:  2018-07-10

5.  Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.

Authors:  I S Nijhof; R W J Groen; H M Lokhorst; B van Kessel; A C Bloem; J van Velzen; R de Jong-Korlaar; H Yuan; W A Noort; S K Klein; A C M Martens; P Doshi; K Sasser; T Mutis; N W C J van de Donk
Journal:  Leukemia       Date:  2015-05-15       Impact factor: 11.528

6.  The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting.

Authors:  T Vaisitti; V Audrito; S Serra; R Buonincontri; G Sociali; E Mannino; A Pagnani; A Zucchetto; E Tissino; C Vitale; M Coscia; C Usai; C Pepper; V Gattei; S Bruzzone; S Deaglio
Journal:  Leukemia       Date:  2014-07-03       Impact factor: 11.528

7.  Identification of human plasma cells with a lamprey monoclonal antibody.

Authors:  Cuiling Yu; Yanling Liu; Justin Tze Ho Chan; Jiefei Tong; Zhihua Li; Mengyao Shi; Dariush Davani; Marion Parsons; Srijit Khan; Wei Zhan; Shuya Kyu; Eyal Grunebaum; Paolo Campisi; Evan J Propst; David L Jaye; Suzanne Trudel; Michael F Moran; Mario Ostrowski; Brantley R Herrin; F Eun-Hyung Lee; Ignacio Sanz; Max D Cooper; Götz Ra Ehrhardt
Journal:  JCI Insight       Date:  2016-03-17

8.  Cell Trafficking in Chronic Lymphocytic Leukemia.

Authors:  Matthew S Davids; Jan A Burger
Journal:  Open J Hematol       Date:  2012-02-21

9.  SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.

Authors:  Cinzia Bologna; Roberta Buonincontri; Sara Serra; Tiziana Vaisitti; Valentina Audrito; Davide Brusa; Andrea Pagnani; Marta Coscia; Giovanni D'Arena; Elisabetta Mereu; Roberto Piva; Richard R Furman; Davide Rossi; Gianluca Gaidano; Cox Terhorst; Silvia Deaglio
Journal:  J Clin Invest       Date:  2015-11-30       Impact factor: 14.808

Review 10.  Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia.

Authors:  Audrey Mohr; Yves Renaudineau; Cristina Bagacean; Jacques-Olivier Pers; Christophe Jamin; Anne Bordron
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.